Operationally Simple and Highly (<i>E</i>)-Styrenyl-Selective Heck Reactions of Electronically Nonbiased Olefins
作者:Erik W. Werner、Matthew S. Sigman
DOI:10.1021/ja203164p
日期:2011.6.29
Simple, mild, and efficient conditions are reported for a Pd(0)-catalyzed Heck reaction that delivers high yields and selectivity for (E)-styrenyl products using electronically nonbiased olefin substrates bearing a range of useful functionality. Preliminary mechanistic studies demonstrate that the σ-donating DMA solvent is crucial for high selectivity. Further studies suggest that the catalyst distinguishes
Compounds of the formula (1) are disclosed which are vitronectin receptor antagonists and are useful in the treatment of osteoporosis:
1
公式(1)的化合物被披露为抗血浆粘附素受体的拮抗剂,并且在骨质疏松症的治疗中有用:1
[EN] VITRONECTIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR DE LA VITRONECTINE
申请人:SMITHKLINE BEECHAM CORPORATION
公开号:WO1999045927A1
公开(公告)日:1999-09-16
(EN) Pharmaceutically active compounds which inhibit the vitronectin receptor and are useful for the treatment of inflammation, cancer and cardiovascular disorders, such as atherosclerosis and restenosis, and diseases wherein bone resorption is a factor, such as osteoporosis.(FR) La présente invention concerne des composés pharmaceutiquement actifs inhibiteurs du récepteur de la vitronectine. Ces composés conviennent pour le traitement de l'inflammation, du cancer, et de troubles cardio-vasculaires tels que l'athérosclérose et la resténose. Ces composés conviennent également pour le traitement de maladies où intervient une résorption osseuse, et notamment l'ostéoporose.